India Proposes Easing Price Controls For Some Makers Of Key Drugs
This article was originally published in PharmAsia News
Executive Summary
India's Cabinet ministers have proposed a certification process to give makers of key drugs an added advantage in setting prices. The proposal sent to the Law Ministry would offer a "gold standard" certificate to companies that meet certain conditions, including having at least 200 scientists on staff. Another requirement would be to have at least one manufacturing facility approved by two foreign regulators and to spend at least 5 percent of turnover on research and development. The certificate would allow them to claim a 200 percent maximum allowable post-manufacturing expense, compared with 150 percent for unqualified firms. The change would affect prices on 354 lifesaving drugs the government wants to bring under price controls. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.